Bavarian Nordic selling Priority Review Voucher

18 December 2019

Denmark’s Bavarian Nordic (OMX: BAVA) yesterday announced that it has entered an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of $95 million. The company did not disclose the name of the buyer.

Bavarian Nordic was awarded the PRV in September 2019 along with approval of Jynneos (MVA-BN) for prevention of smallpox and monkeypox by the US Food and Drug Administration. A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval. Some PRVs have been sold on for more than $300 million.

The transaction remains subject to customary closing conditions, including anti-trust review, which is expected to occur early in 2020. Hence, the sale does not impact the company’s guidance or financial position in 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK